Sopa Photographs | Lightrocket | Getty Photographs
Pfizer’s twice-daily model of its experimental weight reduction tablet has now joined an extended listing of different scrapped medicine that aimed to deal with weight problems however got here with unintended penalties.
The drugmaker on Friday mentioned it would cease growing the twice-daily remedy, danuglipron, after overweight sufferers taking the drug misplaced important weight however skilled excessive charges of adversarial unintended effects in a midstage scientific trial. Pfizer famous that it’ll launch information on a once-daily model of the tablet subsequent 12 months, which can “inform the trail ahead.”
The announcement got here six months after Pfizer scrapped a special once-daily tablet in June, citing elevated liver enzymes. Pfizer’s transfer to drop two weight problems drug candidates in only a few months demonstrates how troublesome it’s to develop an efficient, protected and tolerable remedy for shedding pounds, even after current breakthrough medicines entered the area.
That features Novo Nordisk‘s Wegovy and diabetes remedy Ozempic in addition to Eli Lilly‘s diabetes drug Mounjaro. They’ve all skyrocketed in recognition — and slipped into shortages — during the last 12 months for safely and efficiently inflicting important weight reduction. An estimated 40% of U.S. adults are overweight, making these medicine the pharmaceutical business’s latest money cow.
However earlier than the present weight reduction business gold rush, the trail to treating weight problems was strewn with failures courting again a long time.
The primary cause many experimental therapies have been scrapped by drugmakers, rejected by U.S. regulators or ultimately pulled from the market have been unintended unintended effects, together with elevated liver enzymes, most cancers dangers, cardiovascular dangers and critical psychiatric issues, equivalent to suicide.
Eisai’s lorcaserin
One of the crucial current casualties amongst experimental weight problems medicine is Japanese drugmaker Eisai’s lorcaserin, which was eliminated from the market in 2020 on account of inflicting an elevated threat of most cancers in sufferers.
The Meals and Drug Administration greenlit lorcaserin in 2012 primarily based on a number of scientific trials however required Eisai to conduct a bigger and longer examine on the drug after the approval.
That examine on about 12,000 sufferers over 5 years discovered that extra folks taking lorcaserin have been identified with most cancers in contrast with these taking a placebo, which led the FDA to drag the drug from the market.
Lorcaserin, marketed below the model title Belviq, did not seem to achieve a lot traction whereas it was commercially accessible. In its full-year 2019 earnings, Eisai reported that Lorcaserin had gross sales of $28.1 million within the U.S. for the 12 months. World gross sales of the drug have been about $42 million. Eisai’s complete gross sales for the 12 months have been roughly $4.42 billion.
Sanofi’s rimonabant
An weight problems drug known as rimonabant from Sanofi and Aventis was withdrawn from all markets in 2008 because of the threat of significant psychiatric issues, together with suicide.
Notably, the remedy by no means received approval within the U.S. as a result of a panel of specialists to the FDA rejected the drug amid fears that it could trigger suicidal ideas. However European regulators authorized rimonabant, marketed below the title Acomplia, in 2006 primarily based on in depth scientific trials.
Two years later, European regulators really helpful the suspension of rimonabant after one in every of its committees decided that the dangers of the remedy — notably psychiatric points — outweighed its advantages.
The remedy suppressed urge for food by blocking the receptor of cannabinoid substances within the mind, which performs an necessary function in regulating the physique’s meals consumption and metabolism.
As a consequence of rimonabant’s restricted time available on the market and failure to win U.S. approval, the drug by no means reached Sanofi’s lofty projection that it will ultimately generate $3 billion a 12 months or extra.
Abbott Laboratories’ sibutramine
A number of weight problems medicine have additionally been discontinued, rejected or pulled from the market on account of unintended cardiovascular dangers.
That features sibutramine from Abbott Laboratories, which was as soon as broadly used as a remedy for weight problems together with weight-reduction plan and train.
The drug was first authorized in 1997, however carried warnings about hypertension and a threat of coronary heart assault and stroke in cardiovascular sufferers.
A big, long-term trial on almost 10,000 adults confirmed that sibutramine was related to a big improve in cardiovascular occasions, which prompted regulators within the U.S. and Europe to drag the drug from these markets in 2010.
Gross sales of sibutramine had been dwindling forward of its removing from the market. The drug raked in solely $80 million globally, together with $20 million from the U.S., within the first 9 months of 2010.
Current proof means that the most recent slate of authorized weight reduction medicine might have the other impact on coronary heart well being: Weekly injections of Wegovy slashed the general threat of coronary heart assault, stroke and dying from cardiovascular causes by 20%, in keeping with a current scientific trial.
